IP83: Bladder Cancer: Invasive V
Monday, May 18, 2026 9:30 AM to 11:30 AM · 2 hr. (America/New_York)
147A
Poster and Podium Sessions
Oncology: Bladder
Monday, May 18
IP83-01: Organ-Specific Efficacy of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-02: Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: A multicenter collaborative study
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-03: Association of Prophylactic Corticosteroid Premedication with Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-04: Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-06: Implications of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score as a Predictor of Neoadjuvant Chemotherapy Response in Patients with Muscle-Invasive Bladder Cancer Planning to Undergo Radical Cystectomy
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-07: Comparison of survival outcomes between patients with and without pelvic lymph node dissection in urachal carcinoma
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-08: Pretreatment Pan-Immune-Inflammation Value predicts immune-related interstitial lung disease in genitourinary cancer patients receiving immune checkpoint inhibitors: a single-center cohort of 180 patients
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-09: Upfront perioperative enfortumab vedotin plus pembrolizumab versus risk-adapted adjuvant pembrolizumab or nivolumab: Cost-effectiveness analysis of emerging systemic therapies for cisplatin-ineligible patients with localized muscle-invasive bladd
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-10: Recent trends in utilization of post-cystectomy immunotherapy: results from a national cancer registry.
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
Pietro Brin · Humanitas University
IP83-11: Bladder-sparing Therapy versus Upfront Radical Cystectomy for High-risk Non-muscle-invasive Bladder Cancer: A Propensity Score Matching Analysis
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
Pengchao Li
IP83-12: Prehabilitation before robot-assisted radical cystectomy is associated with reduced 30-day complications and length of stay: a prospective, single-center propensity-weighted cohort study
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-13: Microbiome-Derived Biomarkers Predict Response to Immune Checkpoint Inhibitors in Urologic Malignancies
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-14: Urinary microbiota signatures associated with different types of urinary diversion: a comparative study
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-15: Step-count–guided prehabilitation improves early functional recovery and quality of life after radical cystectomy: interim analysis of the PRACTICE trial (NCT06806059)
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-16: Long-term oncologic and patient-reported quality of life outcomes of partial cystectomy for urothelial carcinoma: a worthwhile bladder preservation modality
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-17: Transurethral Resection (TURBT) and Patient Features Predicting Pathological Response after Radical Cystectomy following a Macroscopically Complete TURBT
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-18: Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-19: Impact of intraoperative fluid infusion on the timing of oral feeding after radical cystectomy
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-20: Does baseline renal function remain prognostic in patients with advanced urothelial carcinoma in the era of modern sequential therapy?
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-21: Clinical determinants of recurrence after radical cystectomy and their time-varying impact: which follow-up for which patient?
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-22: Clinical and genomic characterization of HER2 expression in plasmacytoid urothelial carcinoma: insights from a large institutional cohort
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-23: EVALUATING THE SURROGACY OF INTERMEDIATE CLINICAL ENDPOINTS FOR OVERALL SURVIVAL IN PATIENTS WHO RECEIVED RADICAL CYSTECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOTHERAPY FOR LOCALIZED MUSCLE INVASIVE BLADDER CANCER: A REAL-WORLD COHORT STUDY
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-24: Detectable tissue-informed circulating tumor DNA is associated with progression in patients treated surgically for upper tract urothelial carcinoma
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-25: Functional and biochemical outcomes of prehabilitation before robot-assisted radical cystectomy: a prospective, single-center cohort study
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-26: Real-world treatment patterns and survival outcomes in metastatic urothelial carcinoma in the enfortumab vedotin era: impact of first-line enfortumab vedotin plus pembrolizumab versus platinum chemotherapy
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-27: Can Immunological Markers Predict Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer?
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-28: Prospective assessment of erectile function and oncologic outcomes with nerve-sparing robotic radical cystoprostatectomy with urinary diversion.
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-29: 15-year Oncologic Outcomes after Robot-Assisted radical Cystectomy: Results from The International Robotic Cystectomy Consortium
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
IP83-30: Perioperative Outcomes After Implementation of a Non-Opioid Enhanced Recovery After Surgery (ERAS) Protocol for Patients Undergoing Robotic Cystectomy and Intracorporeal Urinary Diversion
Monday, May 18, 2026 9:30 AM to 11:30 AM
147A
Registered attendees
Yakov Klugman
Medical StudentRoswell Park Comprehensive Cancer Center